Q-omics provides the consensus-scored DUSP28 profile across patient tissues and cancer cell-line models. DUSP28 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DUSP28 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, DUSP28 RNA expression shows 20,689 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, LIHC, and ACC as cancer lineages where DUSP28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP28 survival associations across molecular data types. DUSP28 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP28 RNA expression–survival associations across cancer types. High DUSP28 expression shows unfavorable associations in ACC, KIRC, UVM and LIHC, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for DUSP28 RNA expression.
This table summarizes DUSP28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DUSP28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP28 shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, CHOL, STAD and BRCA. The LIHC box plot shows higher DUSP28 RNA expression in tumor versus normal tissue (log2 FC = +0.646, t-test p < 0.001).
This table shows molecular features associated with DUSP28 in patient tissues and cancer cell lines. In patient samples, DUSP28 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
